Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis.
Forooghian
Farzin
F
Chew
Emily Y
EY
Meyerle
Catherine B
CB
Cukras
Catherine
C
Wong
Wai T
WT
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing / Q000097:blood*; D000068258:Bevacizumab; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy / Q000276:immunology; D008297:Male; D011446:Prospective Studies; D011817:Rabbits; D013618:Tachyphylaxis / Q000276:immunology*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab